ATE291434T1 - Verwendung von angiotensin zur behandlung von krebsmetastasierung - Google Patents
Verwendung von angiotensin zur behandlung von krebsmetastasierungInfo
- Publication number
- ATE291434T1 ATE291434T1 AT99940353T AT99940353T ATE291434T1 AT E291434 T1 ATE291434 T1 AT E291434T1 AT 99940353 T AT99940353 T AT 99940353T AT 99940353 T AT99940353 T AT 99940353T AT E291434 T1 ATE291434 T1 AT E291434T1
- Authority
- AT
- Austria
- Prior art keywords
- angiotensin
- treat cancer
- cancer metastasis
- treatment
- cancer
- Prior art date
Links
- 102000015427 Angiotensins Human genes 0.000 title abstract 3
- 108010064733 Angiotensins Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9818023.5A GB9818023D0 (en) | 1998-08-18 | 1998-08-18 | Cancer treatment |
| GBGB9820000.9A GB9820000D0 (en) | 1998-09-14 | 1998-09-14 | Cancer treatment |
| PCT/GB1999/002727 WO2000010590A2 (en) | 1998-08-18 | 1999-08-18 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE291434T1 true ATE291434T1 (de) | 2005-04-15 |
Family
ID=26314231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99940353T ATE291434T1 (de) | 1998-08-18 | 1999-08-18 | Verwendung von angiotensin zur behandlung von krebsmetastasierung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6852316B2 (de) |
| EP (1) | EP1104305B1 (de) |
| AT (1) | ATE291434T1 (de) |
| AU (1) | AU5434899A (de) |
| DE (1) | DE69924385T2 (de) |
| ES (1) | ES2239454T3 (de) |
| WO (1) | WO2000010590A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043675A2 (de) * | 2006-07-07 | 2009-04-08 | Washington State University Research Foundation | C-met-rezeptorregulierung anhand von angiotensin iv (at4)-rezeptorliganden |
| US8236761B2 (en) * | 2006-07-07 | 2012-08-07 | Washington State University Research Foundation | C-Met receptor regulation by angiotensin IV (AT4) receptor ligands |
| US20090042296A1 (en) * | 2007-03-16 | 2009-02-12 | Marie Callahan | Transfection ready eukaryotic cells |
| US8378100B2 (en) * | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997034627A2 (en) * | 1996-03-19 | 1997-09-25 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. | Protection of hemopoietic cells during chemotherapy or radiotherapy |
-
1999
- 1999-08-18 WO PCT/GB1999/002727 patent/WO2000010590A2/en not_active Ceased
- 1999-08-18 DE DE69924385T patent/DE69924385T2/de not_active Expired - Lifetime
- 1999-08-18 EP EP99940353A patent/EP1104305B1/de not_active Expired - Lifetime
- 1999-08-18 ES ES99940353T patent/ES2239454T3/es not_active Expired - Lifetime
- 1999-08-18 AT AT99940353T patent/ATE291434T1/de not_active IP Right Cessation
- 1999-08-18 AU AU54348/99A patent/AU5434899A/en not_active Abandoned
-
2001
- 2001-02-16 US US09/784,005 patent/US6852316B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2239454T3 (es) | 2005-09-16 |
| AU5434899A (en) | 2000-03-14 |
| DE69924385D1 (de) | 2005-04-28 |
| WO2000010590A2 (en) | 2000-03-02 |
| WO2000010590A3 (en) | 2000-05-18 |
| US20020119142A1 (en) | 2002-08-29 |
| DE69924385T2 (de) | 2006-01-19 |
| EP1104305A2 (de) | 2001-06-06 |
| US6852316B2 (en) | 2005-02-08 |
| EP1104305B1 (de) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| DE69929464D1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
| DE69825286D1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| DE60213116D1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| EP1056458A4 (de) | Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| ATE246924T1 (de) | Neue therapeutische verwendung von nicergoline | |
| DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
| DE60033569D1 (de) | Neue verwendung von prodigiosin zur behandlung von diabetes mellitus | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| DE69806062D1 (de) | Kombinationstherapie zur behandlung von aids | |
| ATE486594T1 (de) | Methode zur behandlung von herzinsuffizienz | |
| ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| DE59904564D1 (de) | Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| DE60327793D1 (de) | Modulation der s6-kinaseaktivität zur behandlung von adipositas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |